Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | PRKCI | P41743 | 4/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424797 | 0.84 | BRD4 (0.60) | BRD4PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL298491 | 0.84 | BRD4 (0.60) | BRD4PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL30669881 | 0.77 | PRKCI (0.49) | BRD4PRKCIAXLAURKBCCNK | |
| SCHEMBL10125070 | 0.71 | BRD4 (0.66) | BRD4PRKCIAURKBCCNKCDK12 | |
| SCHEMBL858602 | 0.71 | BRD4 (0.62) | BRD4PRKCIAURKBCCNKCDK12 | |
| SCHEMBL18680897 | 0.70 | AXL (0.50) | BRD4PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL2992617 | 0.70 | NUDT1 (0.55) | BRD4PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL12605521 | 0.70 | CCNK (0.51) | BRD4PRKCIAXLAURKBCCNK | |
| SCHEMBL858227 | 0.69 | BRD4 (0.75) | BRD4PRKCIAURKBCCNKCDK12 | |
| SCHEMBL12605536 | 0.69 | CCNB2 (0.51) | BRD4TTBK1TTBK2AURKBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339978-A1 | COMPOUNDS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339978-A1 | COMPOUNDS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS | NLN, BDNF, NEFM | BRD4 4007/4885PRKCI 2174/4885AXL 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.